ReviewCurrent atherosclerosis reports2012
Regulation of atherosclerosis and associated risk factors by adenosine and adenosine receptors.
Review in Current atherosclerosis reports, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 36 citations in OpenAlex.
- Adenosine AFrontiers in pharmacology · 2024Article
- Adenosine signaling as target in cardiovascular pharmacology.Current opinion in pharmacology · 2023Review
- Article
- Guanmaitong Granule Attenuates Atherosclerosis by Inhibiting Inflammatory Immune Response in ApoEDrug design, development and therapy · 2022Article
- ADA gene haplotype is associated with coronary-in-stent-restenosis.Molecular biology reports · 2021Article
- Inhibition of microbiota-dependent TMAO production attenuates chronic kidney disease in mice.Scientific reports · 2021Article
- Pharmacological Tuning of Adenosine Signal Nuances Underlying Heart Failure With Preserved Ejection Fraction.Frontiers in pharmacology · 2021Review
- Adenosine and the Cardiovascular System.American journal of cardiovascular drugs : drugs, devices, and other interventions · 2019Review
- Genetic polymorphism of the methotrexate transporter ABCG2, blood pressure and markers of arterial function in patients with rheumatoid arthritis: repeated cross-sectional study.Pharmacogenomics and personalized medicine · 2018Article
- The clinical toxicology of caffeine: A review and case study.Toxicology reports · 2018Review
- Repurposing existing drugs for cardiovascular risk management: a focus on methotrexate.Drugs in context · 2018Review
- Biology of Platelet Purinergic Receptors and Implications for Platelet Heterogeneity.Frontiers in pharmacology · 2018Review
- Methotrexate, blood pressure and markers of arterial function in patients with rheumatoid arthritis: a repeated cross-sectional study.Therapeutic advances in musculoskeletal disease · 2017Article
- Macrophages and the Recovery from Acute and Chronic Inflammation.Annual review of physiology · 2017Review
- Protective Effects of Methotrexate against Proatherosclerotic Cytokines: A Review of the Evidence.Mediators of inflammation · 2017Review
- Adenosine signaling promotes hematopoietic stem and progenitor cell emergence.The Journal of experimental medicine · 2015Article
- Nonantithrombotic medical options in acute coronary syndromes: old agents and new lines on the horizon.Circulation research · 2014Review
- Role of Pannexin-1 hemichannels and purinergic receptors in the pathogenesis of human diseases.Frontiers in physiology · 2014Review
- Methotrexate and cardiovascular prevention: an appraisal of the current evidence.Therapeutic advances in cardiovascular diseaseReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
Adenosine is an endogenous metabolite that has an anti-inflammatory effect across the vasculature. Extracellular adenosine activates 4 G-protein coupled receptors (A1, A3, A2A, and A2B) whose expression varies in different cells and tissues, including the vasculature and blood cells. Higher levels of adenosine are generated during stress, inflammation, and upon tissue damage. Some of the adenosine receptors (AR), such as the A2BAR, are further up-regulated following such stresses. This review discusses the role of adenosine and adenosine receptors in the development of atherosclerosis and some of the risk factors associated with this pathology. These include adenosine receptor-regulated changes in atherosclerosis, blood pressure, thrombosis, and myocardial infarction. Potential therapeutic applications are reviewed, as well as reasons for phenotypic differences occasionally observed between receptor knockout and pharmacological inhibition via drug administration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.